<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002519</url>
  </required_header>
  <id_info>
    <org_study_id>VCC LUN65</org_study_id>
    <secondary_id>P30CA068485</secondary_id>
    <secondary_id>VU-VCC-LUN-65</secondary_id>
    <secondary_id>UPCC-3597</secondary_id>
    <secondary_id>NCI-T92-0246D</secondary_id>
    <nct_id>NCT00002519</nct_id>
  </id_info>
  <brief_title>Paclitaxel Plus Radiation Therapy in Treating Patients With Untreated Stage III Non-small Cell Lung Cancer</brief_title>
  <official_title>PH I Continuous Infusion Taxol in Combination With Thoracic Radiation Therapy in Untreated Locally Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of chemotherapy with paclitaxel in&#xD;
      combination with radiation therapy to the chest in patients with previously untreated stage&#xD;
      III non-small cell lung cancer that cannot be surgically removed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the toxicity and maximum tolerated dose of paclitaxel when combined&#xD;
      with standard thoracic radiotherapy in patients with locally advanced non-small cell lung&#xD;
      cancer. II. Determine the plasma levels of paclitaxel in these patients. III. Determine the&#xD;
      effect of this regimen on the tumor cell cycle distribution in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of paclitaxel. Patients undergo standard thoracic&#xD;
      radiotherapy 5 days a week for 7 weeks. Patients receive paclitaxel IV continuously beginning&#xD;
      48 hours before initiating radiotherapy and continuing until the last day of radiotherapy.&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts&#xD;
      of 3-5 patients receive escalating doses of paclitaxel until the maximum tolerated dose (MTD)&#xD;
      is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 5&#xD;
      patients experience dose-limiting toxicity. Patients are followed monthly for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 3-5 patients per dose level will be accrued for this study&#xD;
      within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <completion_date type="Actual">January 2000</completion_date>
  <primary_completion_date type="Actual">January 2000</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">6</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chemotherapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven previously untreated non-small cell lung&#xD;
        cancer that is not amenable to potentially curative surgery due to the following: Direct&#xD;
        invasion of the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or&#xD;
        carina by tumor (T4) Cytologically positive scalene or supraclavicular nodes Mediastinal or&#xD;
        contralateral hilar nodes 3 cm or greater on CT, with or without pathological confirmation&#xD;
        Pathologically positive mediastinal or contralateral hilar nodes on mediastinoscopy or&#xD;
        Chamberlain procedure (N2 or N3) Medically inoperable stage IIIA disease (e.g., resection&#xD;
        would result in insufficient pulmonary volume) allowed No distant metastases No pleural&#xD;
        effusion (regardless of fluid cytology) Evaluable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: 0-2 Hematopoietic: WBC normal&#xD;
        Platelet count normal Hepatic: Bilirubin no greater than 2 times upper limit of normal&#xD;
        (ULN) Transaminases no greater than 2 times ULN Alkaline phosphatase no greater than 2&#xD;
        times ULN Renal: Creatinine less than 2.0 mg/dL Cardiovascular: No significant coronary&#xD;
        artery disease No documented myocardial infarction No angina, arrhythmia, or congestive&#xD;
        heart failure requiring medication Pulmonary: FEV1 greater than 1 liter pO2 greater than 55&#xD;
        mm Hg on room air pCO2 less than 45 mm Hg on room air Other: No prior severe&#xD;
        hypersensitivity reaction to products containing Cremaphor EL No clinical evidence of&#xD;
        pre-existing polyneuropathy Not pregnant Negative pregnancy test&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior&#xD;
        chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior thoracic irradiation&#xD;
        Surgery: See Disease Characteristics Other: No concurrent medications known to alter&#xD;
        cardiac conduction or cause bradycardia (e.g., digoxin, beta blockers, or calcium channel&#xD;
        blockers)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Carbone, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon-Minnie Pearl Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>May 1, 2013</last_update_submitted>
  <last_update_submitted_qc>May 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2013</last_update_posted>
  <responsible_party>
    <name_title>David Carbone, M.D., Ph.D.</name_title>
    <organization>Vanderbilt-Ingram Cancer Center</organization>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

